Cargando…

CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy

Chemokines and their receptors participate in many biological processes, including the modulation of neuroimmune interactions. Approximately fifty chemokines are distinguished in humans, which are classified into four subfamilies based on the N-terminal conserved cysteine motifs: CXC, CC, C, and CX3...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogacka, Joanna, Pawlik, Katarzyna, Ciapała, Katarzyna, Ciechanowska, Agata, Mika, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779674/
https://www.ncbi.nlm.nih.gov/pubmed/36555280
http://dx.doi.org/10.3390/ijms232415638
_version_ 1784856667607793664
author Bogacka, Joanna
Pawlik, Katarzyna
Ciapała, Katarzyna
Ciechanowska, Agata
Mika, Joanna
author_facet Bogacka, Joanna
Pawlik, Katarzyna
Ciapała, Katarzyna
Ciechanowska, Agata
Mika, Joanna
author_sort Bogacka, Joanna
collection PubMed
description Chemokines and their receptors participate in many biological processes, including the modulation of neuroimmune interactions. Approximately fifty chemokines are distinguished in humans, which are classified into four subfamilies based on the N-terminal conserved cysteine motifs: CXC, CC, C, and CX3C. Chemokines activate specific receptors localized on the surface of various immune and nervous cells. Approximately twenty chemokine receptors have been identified, and each of these receptors is a seven-transmembrane G-protein coupled receptor. Recent studies provide new evidence that CC chemokine receptor 4 (CCR4) is important in the pathogenesis of many diseases, such as diabetes, multiple sclerosis, asthma, dermatitis, and cancer. This review briefly characterizes CCR4 and its ligands (CCL17, CCL22, and CCL2), and their contributions to immunological and neoplastic diseases. The review notes a significant role of CCR4 in nociceptive transmission, especially in painful neuropathy, which accompanies many diseases. The pharmacological blockade of CCR4 seems beneficial because of its pain-relieving effects and its influence on opioid efficacy. The possibilities of using the CCL2/CCL17/CCL22/CCR4 axis as a target in new therapies for many diseases are also discussed.
format Online
Article
Text
id pubmed-9779674
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97796742022-12-23 CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy Bogacka, Joanna Pawlik, Katarzyna Ciapała, Katarzyna Ciechanowska, Agata Mika, Joanna Int J Mol Sci Review Chemokines and their receptors participate in many biological processes, including the modulation of neuroimmune interactions. Approximately fifty chemokines are distinguished in humans, which are classified into four subfamilies based on the N-terminal conserved cysteine motifs: CXC, CC, C, and CX3C. Chemokines activate specific receptors localized on the surface of various immune and nervous cells. Approximately twenty chemokine receptors have been identified, and each of these receptors is a seven-transmembrane G-protein coupled receptor. Recent studies provide new evidence that CC chemokine receptor 4 (CCR4) is important in the pathogenesis of many diseases, such as diabetes, multiple sclerosis, asthma, dermatitis, and cancer. This review briefly characterizes CCR4 and its ligands (CCL17, CCL22, and CCL2), and their contributions to immunological and neoplastic diseases. The review notes a significant role of CCR4 in nociceptive transmission, especially in painful neuropathy, which accompanies many diseases. The pharmacological blockade of CCR4 seems beneficial because of its pain-relieving effects and its influence on opioid efficacy. The possibilities of using the CCL2/CCL17/CCL22/CCR4 axis as a target in new therapies for many diseases are also discussed. MDPI 2022-12-09 /pmc/articles/PMC9779674/ /pubmed/36555280 http://dx.doi.org/10.3390/ijms232415638 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bogacka, Joanna
Pawlik, Katarzyna
Ciapała, Katarzyna
Ciechanowska, Agata
Mika, Joanna
CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy
title CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy
title_full CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy
title_fullStr CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy
title_full_unstemmed CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy
title_short CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy
title_sort cc chemokine receptor 4 (ccr4) as a possible new target for therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779674/
https://www.ncbi.nlm.nih.gov/pubmed/36555280
http://dx.doi.org/10.3390/ijms232415638
work_keys_str_mv AT bogackajoanna ccchemokinereceptor4ccr4asapossiblenewtargetfortherapy
AT pawlikkatarzyna ccchemokinereceptor4ccr4asapossiblenewtargetfortherapy
AT ciapałakatarzyna ccchemokinereceptor4ccr4asapossiblenewtargetfortherapy
AT ciechanowskaagata ccchemokinereceptor4ccr4asapossiblenewtargetfortherapy
AT mikajoanna ccchemokinereceptor4ccr4asapossiblenewtargetfortherapy